Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Gefitinib
Drug ID BADD_D01008
Description Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.
Indications and Usage For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.
Marketing Status approved; investigational
ATC Code L01EB01
DrugBank ID DB00317
KEGG ID D01977
MeSH ID D000077156
PubChem ID 123631
TTD Drug ID D09XZB
NDC Product Code 61200-002; 65344-0029; 54245-1359; 60505-4512; 69339-168; 50742-366; 67184-0531; 0310-0482; 53104-7700; 63850-8070; 0480-4053; 68554-0060; 73377-128; 54893-0036
UNII S65743JHBS
Synonyms Gefitinib | N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide | Iressa | ZD1839 | ZD 1839
Chemical Information
Molecular Formula C22H24ClFN4O3
CAS Registry Number 184475-35-2
SMILES COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rash pustular23.03.10.003; 11.01.12.002--
Respiratory failure22.02.06.002; 14.01.04.0030.000616%
Scab23.03.03.0040.000112%Not Available
Schizophrenia19.03.04.0010.000168%Not Available
Scrotal oedema21.12.02.001--Not Available
Seborrhoeic dermatitis23.03.04.018--Not Available
Shock24.06.02.0020.000112%Not Available
Sinus arrhythmia02.03.03.008--Not Available
Skin disorder23.03.03.0070.000884%Not Available
Skin exfoliation23.03.07.0030.000302%Not Available
Skin fissures23.03.03.008--Not Available
Skin reaction23.03.03.013; 10.01.03.0190.000112%Not Available
Skin ulcer24.04.03.007; 23.07.03.0030.000336%
Small cell lung cancer22.08.01.013; 16.19.08.0030.000448%Not Available
Squamous cell carcinoma16.16.01.0020.000336%Not Available
Squamous cell carcinoma of lung22.08.01.014; 16.19.01.0060.000224%Not Available
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 11.07.01.005; 10.01.01.0450.000112%
Stomatitis07.05.06.0050.000392%
Tachypnoea22.02.01.0140.000168%Not Available
Tenderness08.01.08.005--Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombophlebitis24.01.02.001--Not Available
Toxic epidermal necrolysis10.01.01.006; 23.03.01.008; 12.03.01.015; 11.07.01.006--
Ulcer08.03.06.001--Not Available
Upper gastrointestinal haemorrhage24.07.02.024; 07.12.02.0060.000168%
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Vasculitis24.12.04.027; 10.02.02.0060.000246%
Vomiting07.01.07.003--
The 6th Page    First    Pre   6 7 8 9    Next   Last    Total 9 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene